Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients
Colorectal Cancer Liver Metastases
DRUG: CapOx(Capecitabine+ Oxaliplatin)|DRUG: Bevacizumab|DRUG: Nivolumab
R0 recession rate, Percentage of patients who achieve R0 resection, 10 weeks|Pathological complete response rate, Percentage of patients who achieve pathological complete response (pCR) based on local investigator, 15 weeks|Tumor regression grade (TRG）, 15 weeks
Objective response rate, Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST)., Up to 3 years|Event free survival, Measure of time from study treatment to disease progression or death., Up to 3 years|Disease-free surviva, Measure of time from the date of surgery to disease relapse or death., Up to 3 years|One-year or two-year disease-free survival rate, Percentage of patients who achieve disease-free survival lasting for more than one and two years respectively from the date of surgery., Up to 2 years|One-year or two-year overall survival rate, Percentage of patients who achieve survival for more than one and two years respectively from date of first dose., Up to 2 years|Incidence of Treatment-Related Adverse Events, Number of adverse events, Until 30 days after the last treatment|Quality of life score (QoL score）, Assessment of life quality based on EORTC QLQ-C30, Until 30 days after the last treatment
This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients